News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis in the News - 6 October 2015
Following Pharmaxis recent announcement of a successful phase 1 clinical trial of the drug it sold to Boehringer Ingelheim earlier this year, Pharmaxis chief executive officer Gary Phillips has been interviewed by several journalists and analysts. Those interviews currently available on the internet may be accessed from the following links.
Australian Financial Review (article):
”Pharmaxis has a new business model – is it now the least risky biotech stock?”
ABC Online (article & interview):
“Valley of death' journey for Australian biotech to pharmacy shelves”
CommSec TV - Executive Series
CommSec’s Tom Piotrowski speaks with Pharmaxis Limited (PXS) CEO, Gary Phillips about the company’s successful Phase 1 trial results for a drug which it has sold to Germany’s Boehringer Ingelheim.
Proactive Investors (interview):
Pharmaxis' CEO Gary Phillips talks clinical trials and Boehringer deal with Proactive Investors
Bioshares article published 25 September 2015:
Pharmaxis Explains Different Approaches To NASH, Adds More Detail To BI Deal
Biotech Daily
Pharmaxis, Boehringer PXS4728A Meets Phase I Endpoints
Read also Pharmaxis latest Corporate Summary
Read full media release - pdf